Telomir Pharmaceuticals Reports Q1 2026 Financial Results with Reduced Net Loss

Telomir Pharmaceuticals, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $990,947, a significant reduction from the $2,179,828 loss recorded in the same period of 2025. The company did not generate any revenue during the quarter, consistent with its ongoing status as a clinical-stage biotechnology firm focused on developing therapeutics for cancer and age-related diseases. Total operating costs for the quarter were $1,041,336, down from $2,187,782 in the prior year, primarily due to a decrease in general and administrative expenses, which fell from $1,850,786 to $573,539.

The company’s cash position as of March 31, 2026, stood at approximately $5.6 million, a decrease from $7.3 million at the end of 2025. This decline was attributed to cash used in operations, which amounted to $1.8 million for the quarter. Notably, the company’s total liabilities decreased from $1.4 million at the end of 2025 to $827,310, reflecting a reduction in trade accounts payable and accrued liabilities. Stockholders’ equity also decreased to $4.96 million from $5.91 million, primarily due to the net loss incurred during the quarter.

In terms of strategic developments, Telomir completed a merger with TELI Pharmaceuticals, Inc. on April 22, 2026, which was approved by stockholders on March 23, 2026. This merger consolidates the rights to Telomir-1 (Telomir-Zn), the company’s lead investigational candidate, under a single corporate structure. As part of the merger, Bayshore Trust, a related party, contributed $1 million in cash and committed to provide up to an additional $4 million in equity funding contingent upon achieving specific regulatory and clinical milestones.

Operationally, the company is advancing its clinical trial for Telomir-1, having received FDA clearance for its Investigational New Drug application to evaluate the candidate in patients with advanced or metastatic triple-negative breast cancer. The company is also conducting preclinical research to explore the potential applications of Telomir-1 across various disease areas. As of the end of the first quarter, Telomir had 34,380,971 shares of common stock outstanding, with no significant changes in employee headcount reported.

Looking ahead, Telomir Pharmaceuticals anticipates that its cash reserves will be sufficient to fund operations through the first quarter of 2027. However, the company acknowledges the need for additional funding to support ongoing clinical trials and operational expenses. The management has indicated that it will continue to seek new sources of financing to ensure the advancement of its product candidates and to maintain operations in the face of ongoing losses.